Table of Contents Author Guidelines Submit a Manuscript
Gastroenterology Research and Practice
Volume 2010 (2010), Article ID 758397, 7 pages
Clinical Study

Troxipide in the Management of Gastritis: A Randomized Comparative Trial in General Practice

Medical Services Department, Zuventus Healthcare Ltd, 5119, ‘D’ Wing, Oberoi Garden Estates, Chandivali, Mumbai 400072, India

Received 2 August 2010; Revised 29 September 2010; Accepted 13 October 2010

Academic Editor: R. Fass

Copyright © 2010 Bhupesh Dewan and Aarthi Balasubramanian. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Background. A trial of empirical acid-suppressive therapy is the usual practice for most patients with symptoms of gastritis in primary care. Aim. To assess the relative efficacy of Troxipide and Ranitidine in patients with endoscopic gastritis over a four-week period. Methods. In all, 142 patients were randomized to Troxipide (100 mg tid) or Ranitidine (150 mg bid) for a period of four weeks. The severity of the signs of endoscopic gastritis at baseline and week 4 using a four-point scale and the subjective symptom severity at baseline and week 2 & week 4 using a Visual analog scale (VAS) were documented. Results. Troxipide was found to be superior to Ranitidine for both, the complete resolution and improvement of endoscopic gastritis. Higher proportion of patients showed complete healing of erosions (88.14%), oozing (96.77%), and edema (93.88%) with Troxipide as compared to Ranitidine ( 𝑃 < . 0 1 ). Patients receiving Troxipide also showed a greater improvement in the VAS scores for abdominal pain, bloating, and heartburn ( 𝑃 < . 0 1 ). Both the drugs were found to be well tolerated. Conclusion. In patients with endoscopic gastritis, Troxipide, with its superior rate of improvement, resolution of signs, and subjective clinical symptoms, can be considered as an alternative to the commonly used antisecretory agents.